JP7678793B2 - エンシフェントリンを含む医薬組成物 - Google Patents

エンシフェントリンを含む医薬組成物 Download PDF

Info

Publication number
JP7678793B2
JP7678793B2 JP2022508963A JP2022508963A JP7678793B2 JP 7678793 B2 JP7678793 B2 JP 7678793B2 JP 2022508963 A JP2022508963 A JP 2022508963A JP 2022508963 A JP2022508963 A JP 2022508963A JP 7678793 B2 JP7678793 B2 JP 7678793B2
Authority
JP
Japan
Prior art keywords
dry powder
pharmaceutical composition
particles
ensifentrine
powder pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022508963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550664A5 (https=
JP2022550664A (ja
Inventor
リオネル スパーゴ、ピーター
ジェームズ フレンチ、エドワード
Original Assignee
ヴェローナ ファーマ ピーエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴェローナ ファーマ ピーエルシー filed Critical ヴェローナ ファーマ ピーエルシー
Publication of JP2022550664A publication Critical patent/JP2022550664A/ja
Publication of JP2022550664A5 publication Critical patent/JP2022550664A5/ja
Application granted granted Critical
Publication of JP7678793B2 publication Critical patent/JP7678793B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022508963A 2019-08-12 2020-08-12 エンシフェントリンを含む医薬組成物 Active JP7678793B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1911517.9A GB201911517D0 (en) 2019-08-12 2019-08-12 Pharmaceutical composition
GB1911517.9 2019-08-12
PCT/GB2020/051914 WO2021028679A1 (en) 2019-08-12 2020-08-12 Pharmaeutical composition comprising ensifentrine

Publications (3)

Publication Number Publication Date
JP2022550664A JP2022550664A (ja) 2022-12-05
JP2022550664A5 JP2022550664A5 (https=) 2023-08-08
JP7678793B2 true JP7678793B2 (ja) 2025-05-16

Family

ID=67991071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022508963A Active JP7678793B2 (ja) 2019-08-12 2020-08-12 エンシフェントリンを含む医薬組成物

Country Status (15)

Country Link
US (1) US20220265549A1 (https=)
EP (1) EP4013384A1 (https=)
JP (1) JP7678793B2 (https=)
KR (1) KR20220045214A (https=)
CN (1) CN114286672A (https=)
AU (1) AU2020328223B2 (https=)
BR (1) BR112022002630A2 (https=)
CA (1) CA3144713A1 (https=)
GB (1) GB201911517D0 (https=)
IL (2) IL326396A (https=)
MX (1) MX2022001724A (https=)
MY (1) MY208922A (https=)
PH (1) PH12022550322A1 (https=)
WO (1) WO2021028679A1 (https=)
ZA (1) ZA202201322B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7307855B2 (ja) * 2019-10-11 2023-07-12 テレフオンアクチーボラゲット エルエム エリクソン（パブル） 無線通信ネットワークにおける設定ダウンリンク送信および動的ダウンリンク送信をハンドリングする方法および装置
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN120787157A (zh) * 2022-10-20 2025-10-14 维罗纳制药公司 使用恩塞芬汀治疗特发性肺纤维化
KR20250087621A (ko) * 2022-10-28 2025-06-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 이소퀴놀리논계 화합물을 포함하는 약학적 조성물 및 이의 제조 방법
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
AU2024309346C1 (en) 2023-06-26 2026-03-12 Verona Pharma Plc Particulate composition comprising ensifentrine
WO2025052119A1 (en) * 2023-09-06 2025-03-13 Verona Pharma Plc Ensifentrine for use in treating chronic obstructive pulmonary disease (copd)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011746A1 (de) 1991-12-10 1993-06-24 Boehringer Ingelheim Kg Inhalationspulver und verfahren zu ihrer herstellung
US20070202053A1 (en) 2004-03-17 2007-08-30 Chiesi Farmaceutici S.P.A. Pharmaceutical Formulations For Dry Powder Inhalers Comprising A Low-Dosage Strength Active Ingredient
WO2015173551A1 (en) 2014-05-12 2015-11-19 Verona Pharma Plc New treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60005493T2 (de) 1999-03-31 2004-07-01 Vernalis Ltd., Wokingham Pyrimido[6,1-a]isochinolinonderivate
EP2968312B1 (en) * 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
MY196072A (en) 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011746A1 (de) 1991-12-10 1993-06-24 Boehringer Ingelheim Kg Inhalationspulver und verfahren zu ihrer herstellung
US20070202053A1 (en) 2004-03-17 2007-08-30 Chiesi Farmaceutici S.P.A. Pharmaceutical Formulations For Dry Powder Inhalers Comprising A Low-Dosage Strength Active Ingredient
WO2015173551A1 (en) 2014-05-12 2015-11-19 Verona Pharma Plc New treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Pharmacology and Experimental Therapeutics，2006年，318 (2)，p.840-848，DOI:10.1124/jpet.105.099192
粉体工学会誌，2017年，54 巻 2 号，p.82-89，DOI: 10.4164/sptj.54.82

Also Published As

Publication number Publication date
KR20220045214A (ko) 2022-04-12
ZA202201322B (en) 2024-06-26
IL290447A (en) 2022-04-01
CN114286672A (zh) 2022-04-05
BR112022002630A2 (pt) 2022-05-03
WO2021028679A1 (en) 2021-02-18
GB201911517D0 (en) 2019-09-25
WO2021028679A8 (en) 2022-02-24
CA3144713A1 (en) 2021-02-18
AU2020328223B2 (en) 2025-09-04
JP2022550664A (ja) 2022-12-05
US20220265549A1 (en) 2022-08-25
IL290447B1 (en) 2026-03-01
IL326396A (en) 2026-04-01
PH12022550322A1 (en) 2023-02-13
MY208922A (en) 2025-06-11
MX2022001724A (es) 2022-03-11
EP4013384A1 (en) 2022-06-22
AU2020328223A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
JP7678793B2 (ja) エンシフェントリンを含む医薬組成物
DK1267866T4 (en) Treatment of respiratory diseases
AU2021200503B2 (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
JP2015519394A (ja) キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法
EA031566B1 (ru) Единичная лекарственная форма в форме композиции сухого порошка, применение единичной лекарственной формы и ингалятор сухого порошка, заполненный единичной лекарственной формой
CN105101955A (zh) 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物
JP6415536B2 (ja) ブデソニドおよびフォルモテロールを含む医薬組成物
US10786450B2 (en) Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
RU2825334C2 (ru) Фармацевтическая композиция, содержащая энсифентрин
AU2021200396B2 (en) Pharmaceutical composition containing budesonide and formoterol
RU2422144C2 (ru) Применение солей тиотропия для лечения тяжелых форм персистирующей астмы
JP2022549445A (ja) 吸入用乾燥粉末製剤のための新規担体粒子
EA015353B1 (ru) Применение солей тиотропия для лечения персистирующей астмы средней тяжести

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220318

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20220307

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250502

R150 Certificate of patent or registration of utility model

Ref document number: 7678793

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150